Prevention & lipidsCohort study
Allocation of Semaglutide According to Coronary Artery Calcium and BMI
- Prospective cohort study (secondary analysis of MESA) with modelled NNT
- SELECT trial risk reductions applied to observed incidence rates
Authors' conclusion
Measurement of CAC may enhance value of care with weight loss dose semaglutide in those without diabetes or clinical CVD, improving allocation of a limited health care resource.
Study context
- Population
- MESA participants without DM or clinical cardiovascular disease (CVD) meeting BMI criteria for semaglutide, with coronary artery calcium (CAC) scoring on noncontrast cardiac CT49% had CAC
- Participants
- 3,129 participants
- Exposure
- CAC ≥300 vs CAC = 0
- Outcome
- Major adverse cardiovascular events (MACE)
Main finding
As reported in the abstract
Hazard ratio
2.16
95% CI 1.57–2.99
P < 0.001
By group
CAC = 0
653
5-year NNT (semaglutide)
CAC ≥300
79
5-year NNT (semaglutide)
CAC ≥300 vs CAC = 0
HR 2.16 (95% CI 1.57–2.99); P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | CAC = 0 | CAC ≥300 | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| HF | 2.80 (1.81–4.35) | P < 0.001 | |||
| 5-year NNT (semaglutide) | 1,094 | 144 | |||
| CKD | 1.59 (1.15–2.22) | P = 0.006 | |||
| 5-year NNT (semaglutide) | 1,044 | 144 | |||
| All-cause mortality | 1.35 (1.08–1.69) | P = 0.009 | |||
| 5-year NNT (semaglutide) | 408 | 98 | |||
| 0.20.5125Hazard ratio (log scale) |
Original publication
Allocation of Semaglutide According to Coronary Artery Calcium and BMI. JACC Cardiovasc Imaging. Published 8 January 2025. doi:10.1016/j.jcmg.2024.10.004
Summarised from the published abstract; every number is checked against it